Arvinas (ARVN) Interest & Investment Income (2017 - 2026)
Arvinas (ARVN) recorded quarterly Interest & Investment Income of $6.4 million in Q1 2026, down 13.51% quarter-over-quarter from $7.4 million in Q4 2025, and down 45.3% on a YoY basis from $11.7 million in Q1 2025.
Arvinas (ARVN) Interest & Investment Income (2017 - 2026) Analysis & Trends
Arvinas' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 45.3% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $33.1 million (down 36.95% YoY), while the FY2025 annual figure was $38.4 million, down 29.93% from the prior year.
- Interest & Investment Income was $6.4 million for Q1 2026 at Arvinas, down from $7.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $14.3 million in Q3 2024 to a low of $1.2 million in Q1 2022.
- Historically, Interest & Investment Income has averaged $8.9 million across 5 years, with a median of $9.0 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 822.55% in 2022, then tumbled 45.3% in 2026.
- A 5-year view of Interest & Investment Income shows it stood at $5.7 million in 2022, then soared by 114.04% to $12.2 million in 2023, then grew by 5.74% to $12.9 million in 2024, then sank by 42.64% to $7.4 million in 2025, then decreased by 13.51% to $6.4 million in 2026.
- The last three Interest & Investment Income figures came in at $6.4 million (Q1 2026), $7.4 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 6.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Sep 30, 2024 | 14.30 Mn |
| Jun 30, 2024 | 13.60 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Dec 31, 2023 | 12.20 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 7.60 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 3.40 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 620,912.00 |
| Sep 30, 2021 | 368,545.00 |
| Jun 30, 2021 | 360,160.00 |